

EURONANOMED

JOINT TRANSNATIONAL CALL FOR PROPOSALS (2020) FOR “EUROPEAN INNOVATIVE RESEARCH & TECHNOLOGICAL DEVELOPMENT PROJECTS IN NANOMEDICINE”

PRELIMINARY ANNOUNCEMENT

EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research and innovation programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine. Through 10 successful Joint Transnational Calls launched from 2009 to 2019, EuroNanoMed has allocated about 86 **Million euros** to fund 100 transnational projects in nanomedicine.

Under the umbrella of EuroNanoMed III, the **11th Joint Transnational Call** will be launched for funding multilateral innovative research projects on nanomedicine:

- This call is likely to open on: **14th November 2019**
- Submission deadline for pre-proposals: **21st January 2020**
- Submission deadline of full proposals: **10th June 2020**

|| AIMS OF THE CALL

EuroNanoMed aims (i) to support **translational research projects** that combine innovative approaches in the field of nanomedicine and (ii) to encourage and enable **transnational collaboration between public and private research groups** from academia, clinical/public health research or research teams from industrial enterprises (all size). The participation of **Medical Doctors** and **SMEs** will be strongly encouraged.

|| TOPICS OF THE CALL

Project proposals will address multidisciplinary and translational research. Project proposals will need to cover at least one of the following areas that are equal in relevance for this call:

- a) **Regenerative medicine**
- b) **Diagnostics**
- c) **Targeted delivery systems**

At the end, projects should fall within, but are not limited to, Technology Readiness Levels (TRL)¹ 3-6, although for being realistic and coherent with the characteristics of the call, projects should propose advancements for a maximum of two TRL levels during their lifetime.

|| GENERAL CONDITIONS FOR APPLICATION

A consortium applying to this call will be required to include research group(s) from **at least 2 of the 3 following categories**, if eligible according to relevant national/regional funding organisations' regulations for research funding²:

- **Academia** (research teams working in universities, other higher education institutions or research institutes);
- **Clinical/public health sector** (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of Medical Doctors is encouraged;
- **Enterprise** (all sizes of private companies). Participation of small and medium-size enterprises (SMEs) will be encouraged.

²Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EuroNanoMed funding organisation respective of the country/region from which applicants have applied. The applications are therefore subject to eligibility criteria of individual funding organisations. Applicants are strongly advised to contact their national representatives as soon as possible in order to confirm their eligibility.

Only transnational projects will be funded. Each consortium submitting a proposal will need to involve a **minimum of 3 eligible and a maximum of 5 eligible partners from at least 3**

¹ Horizon 2020 scale for TRL:

https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-g-trl_en.pdf

different countries participating to the call (see list below) though no more than 2 eligible partners from the same country participating in the call will be accepted in one consortium. Research groups not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. However, no more than one research group with own funding can be included in a consortium. The coordinator must be eligible to be funded by the participating funding organisations.

The maximum number of partners will possibly be increased from **5 to 7 (including eligible for funding and non-eligible for funding research groups)** if partners from these participating countries, whose scientific community has been under-represented in past EuroNanoMed calls: **Bulgaria, Czech Republic, Estonia, Latvia, Lithuania, Romania, Slovakia, Taiwan, and Turkey:**

Number of partners requesting funding (eligible partners)	3	4	5	6 (only with at least one underrepresented)	7 (only with at least 2 underrepresented)
Possible number of additional partners with own funding	1	1	1	1	0

|| POTENTIAL PARTICIPATING COUNTRIES AND REGIONS

Belgium, Bulgaria, Canada (Quebec), Czech Republic, Estonia, France, Greece, Israel, Italy, Latvia, Lithuania, Norway, Poland, Romania, Slovakia, Spain, Taiwan and Turkey (see the contact list below).

Please note that funding from Norway will only be eligible to projects in the medical domain of cancer.

Please Note:

The information provided in this pre-announcement is indicative (not legally binding) and may be subject to changes. Additional funding organisations might join the call before the official publication.

Interested applicants are encouraged to initiate scientific contacts with potential project partners:

- Look at the **Nanomedicine Map** to find potential partners:

<http://www.etp-nanomedicine.eu/public/public/european-nanomedicine-map>

- Use the **EuroNanoMed partnering tool**:

<http://www.euronanomed.net/partner-search/list-of-searches-and-offers/>

Final call information is expected to be published on the EuroNanoMed website by **mid-November 2019**. For more info please visit: <http://www.euronanomed.net/>

CONTACT DETAILS OF POTENTIAL PARTICIPATING MEMBERS

Country	Funding Organisation	Contact point	Email
Belgium	FRS-FNRS	Joël Groeneveld	joel.groeneveld@frs-fnrs.be
Bulgaria	BNSF	Nikolai Lazarov	nikolai.lazarov@gmail.com
Canada (Québec)	FRQS	Maxime Beaudoin	Maxime.Beaudoin@frq.gouv.qc.ca
Czech Republic	TACR	Kristina Nehilčová	kristina.nehilcova@tacr.cz
Estonia	ETAg	Aare Ignat	Aare.ignat@etag.ee
France	ANR	Martine Batoux Marie-Pierre Gosselin	ENMCalls@anr.fr
Greece	GSRT	Paraskevi Afentaki Anna Rosenberg	pafe@gsrt.gr a.rosenberg@gsrt.gr
Israel	CSO-MOH	Irit Allon Orly Spivak	Irit.allon@moh.gov.il orlee.f@gmail.com
Italy	IMH	Maria Grazia Mancini	mg.mancini-esterno@sanita.it research.eu.dgric@sanita.it
Latvia	VIAA	Linda Vecbiškēna	Linda.Vecbiskena@viaa.gov.lv
Lithuania	RCL	Živilė Ruželė	zivile.ruzele@lmt.lt
Norway	RCN	Cecilie A. Mathiesen	cam@rcn.no
Poland	NCBR	Marcin Chmielewski	Marcin.Chmielewski@ncbr.gov.pl
Romania	UEFISCDI	Mihaela Manole	mihaela.manole@uefiscdi.ro
Slovakia	SAS	Katarina BIBOVA	bibova@up.upsav.sk
Spain	AEI	Beatriz Gomez	beatriz.gomez@aei.gob.es
Spain	ISCIII	Astrid Valencia Quiñones	ma.valencia@isciii.es
Spain	CDTI	Héctor González	hector.gonzalez@cdti.es
Taiwan	MOST	Ching-Mei Tang	cmtom@most.gov.tw
Turkey	TUBITAK	Alperen Erdoğan	alperen.erdogan@tubitak.gov.tr